Search Results - "Swan, Hallie"

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer by Lui, Goldie Y.L., Shaw, Reid, Schaub, Franz X., Stork, Isabella N., Gurley, Kay E., Bridgwater, Caroline, Diaz, Robert L., Rosati, Rachele, Swan, Hallie A., Ince, Tan A., Harding, Thomas C., Gadi, Vijayakrishna K., Goff, Barbara A., Kemp, Christopher J., Swisher, Elizabeth M., Grandori, Carla

“…Homologous recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers, for which PARP inhibitors (PARPi) are becoming a…”
Get full text

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing by Gray, Heidi J., Chatterjee, Payel, Rosati, Rachele, Appleyard, Lauren R., Durenberger, Grace J., Diaz, Robert L., Swan, Hallie A., Peretti, Danielle, Pollastro, Maddy, Ainge, Trevor, Kapeli, Katannya, Pereira, Shalini, Margossian, Astrid L., Banda, Kalyan, Goff, Barbara A., Swisher, Elizabeth M., Bernard, Brady, Kemp, Christopher J., Grandori, Carla

“…Low-grade serous ovarian cancer (LGSOC) typically responds poorly to standard platinum-based chemotherapy and new therapeutic approaches are needed. We…”
Get full text

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer by Xu, Chang, Nikolova, Olga, Basom, Ryan S, Mitchell, Ryan M, Shaw, Reid, Moser, Russell D, Park, Heuijoon, Gurley, Kay E, Kao, Michael C, Green, Carlos L, Schaub, Franz X, Diaz, Robert L, Swan, Hallie A, Jang, In S, Guinney, Justin, Gadi, Vijayakrishna K, Margolin, Adam A, Grandori, Carla, Kemp, Christopher J, Méndez, Eduardo

“…Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with high mortality and a lack of targeted therapies. To identify and…”
Get full text

Abstract PS4-01: Clinical and genomic correlation of a CLIA certified organoid based functional test in breast cancer patients by Margossian, Astrid, Richardson, Anne, Pollastro, Madison, Churchill, Michael, Schaub, Franz, Pereira, Shalini, Chatterjee, Payel, Rosati, Rachele, Appleyard, Lauren, Durenberger, Grace, Federation, Alex, Whitney, G. Adam, Swan, Hallie, Ainge, Trevor, Diaz, Robert, Hunter, Natasha, Gamboa, Eric, Kemp, Chris, Gadi, Vijayakrishna, Grandori, Carla

“…Abstract The goal of precision medicine is to match the right drug to the right patient. However, every individual cancer carries a unique and complex mosaic…”
Get full text

Abstract 2625: Patient derived organoids to guide personalized neuroblastoma treatment by Rosati, Rachele, Swan, Hallie A., Scolaro, Laura, Krytska, Kateryna, Maris, John M., Schaub, Franz X., Grandori, Carla

“…Abstract Goal: Neuroblastoma (NBL) is the second most frequent pediatric solid tumor. We have seen an increase in survival for children with NBL, however…”
Get full text

Abstract 818: Organoid based functional test to predict personalized treatment in cholangiocarcinoma by Margossian, Astrid, Schaub, Franz X., Richardson, Annie, Churchill, Michael, Rosati, Rachele, Dullea, Alexandra, Whitney, G Adam, Swan, Hallie, Diaz, Robert, Appleyard, Lauren, Gadi, Vijaykrishna, Zarrinpar, Ali, Javle, Milind, Kemp, Christopher, Pereira, Shalini, Grandori, Carla

“…Abstract Introduction: It is difficult to find targeted therapies that work across the genetically diverse Cholangiocarcinoma (CCA) patient population; genomic…”
Get full text

Abstract 534: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities by Lui, Goldie, Richardson, Anne, Chatterjee, Payel, Pollastro, Madison, Lints, Mia, Peretti, Danielle, Rosati, Rachele, Appleyard, Lauren, Durenberger, Grace, Diaz, Robert, Gurley, Kay, Stork, Isabella, Whitney, Adam, Kapeli, Katannya, Swan, Hallie, Memari, Yasin, Davies, Helen, Nik-Zainal, Serena, Banda, Kalyan, Gray, Heidi, Goff, Barbara, Swisher, Elizabeth, Margossian, Astrid, Kemp, Christopher, Grandori, Carla

“…Abstract Background: Clinically approved targeted therapies for ovarian cancer patients are currently limited to PARP inhibitors and bevacizumab. To improve…”
Get full text

A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients by Margossian, Astrid, Pollastro, Madison, Richardson, Annie, Chatterjee, Payel, Lints, Mia, Peretti, Danielle, Rosati, Rachele, Appleyard, Lauren, Durenberger, Grace, Whitney, G. Adam, Swan, Hallie, Pereira, Shalini, Diehl, Adam, Kemp, Christopher J, Goff, Barbara Ann, Banda, Kalyan, Harris, William Proctor, Swisher, Elizabeth M., Gadi, Vijayakrishna K., Grandori, Carla

“…Abstract only 2602 Background: A CLIA-certified organoid based drug sensitivity assay (a cancer organogram) has been developed for all solid tumors. An…”
Get full text

Abstract 582: Accelerating drug development with a CLIA approved functional test using patient derived organoids by Schaub, Franz X., Churchill, Michael J., Swan, Hallie A., Rosati, Rachele, Watt, Roland M., Shaw, Reid C., Murphy, Stephanie A., Diaz, Robert L., Pereira, Shalini C., Grandori, Carla

“…Abstract The pool of targeted therapies is expanding steadily providing novel treatment opportunities. However, the process of expanding indications and…”
Get full text

Abstract 1605: Personalization of cancer treatments with a CLIA-certified high-complexity and high-throughput drug sensitivity test by Swan, Hallie A., Churchill, Michael J., Rosati, Rachele, Schaub, Franz X., Shaw, Reid C., Watt, Roland M., Mendez, Eduardo, Kemp, Christopher J., Gadi, Vijayakrishna K., Murphy, Stephanie A., Bernard, Brady, Diaz, Robert L., Pereira, Shalini C., Grandori, Carla

“…Abstract In June 2017, SEngine Precision Medicine (Seattle, WA USA) obtained CLIA certification for the first high-complexity and high throughput organotypic…”
Get full text

Abstract 1619: Personalized medicine: A CLIA-certified high-throughput drug screening platform for ovarian cancer by Swan, Hallie A., Rosati, Rachele, Bridgwater, Caroline, Churchill, Michael J., Watt, Roland M., Shaw, Reid C., Murphy, Stephanie A., Diaz, Robert L., Pereira, Shalini C., Schaub, Franz X., Grandori, Carla

“…Abstract Background: Metastatic disease in ovarian cancer is difficult to treat and patients often exhaust standard-of-care regimens. To get a better…”
Get full text

Abstract 1603: Patient derived tumor organoids identify actionable targets in heavily pretreated metastatic breast cancer patients by Churchill, Michael J., Schaub, Franz X., Swan, Hallie A., Rosati, Rachele, Yan, Fengting, Shaw, Reid C., Gurley, Kay E., Diaz, Robert L., Pereira, Shalini C., Grandori, Carla, Kemp, Christopher J., Gadi, Vijayakrishna K.

“…Abstract Recurrent metastatic breast cancer is difficult to treat and patients often exhaust standard-of-care regimens. P.A.R.I.S. is a CLIA certified high…”
Get full text

Abstract 3399: Tumor organoid based drug sensitivity testing in ovarian cancer identifies exceptional responders to targeted therapies by Prechtl, Amanda M., Al-Aloosi, Marwah, Chatterjee, Payel, Rosati, Rachele, Velazquez, Samantha, Appleyard, Lauren, Durenberger, Grace, Cordero, Cristina, Diaz, Robert, Swan, Hallie, Bernard, Brady, Mukherjee, Siddhartha, Goff, Barbara, Swisher, Elizabeth, Gray, Heidi, Banda, Kalyan, Kemp, Christopher, Grandori, Carla

“…Abstract Background: Over 50% of patients with ovarian cancer (OVCA) succumb to their disease within five years from diagnosis, highlighting the need for new…”
Get full text